title: A new HC-A II solution for kidney preservation: A multi-center randomized controlled trial in China.
abstract: BACKGROUND
  Hypertonic citrate adenine (HC-A) solution, containing citrate and adenine, has become the most widely used preservation solution in isolated kidney preservation in China. More than 30 years of clinical application has demonstrated that HC-A is safe and effective. With higher requirement for kidney preservation and less tolerance of preservation-related graft dysfunction, a new solution, HC-A II, for kidney preservation was developed by Shanghai Changzheng Hospital.
  
  
  METHODS
  Upon approval from the State Food and Drug Administration of China (SFDA), a multi-center randomized controlled trial was performed to study the efficacy and safety of HC-A II in kidney preservation from 2008 to 2012, using histidine-tryptophan-ketoglutarate solution (HTK) as control (HC-A, n=137, and HTK, n=140). There were no differences with regard to donor and recipient demographics or cold ischemia.
  
  
  RESULTS
  The trial results showed no significant difference in DGF rate, or patient or graft survival between the 2 groups. No significant difference between the 2 groups was found in the percentage of patients whose serum creatinine (SCr) test results returned to normal within 28 days (P>0.05), nor were there a significant difference in safety evaluation (P>0.05).
  
  
  CONCLUSIONS
  HC-A II and HTK appear to have similar efficacy in isolated kidney preservation.
authors.affiliation: Organ Transplantation Institute of PLA, Changzheng Hospital, Second Military Medical University, Shanghai, China (mainland).
authors.forename: Mingxing
authors.initials: M
authors.lastname: Sui
authors.affiliation: Organ Transplantation Institute of PLA, Changzheng Hospital, Second Military Medical University, Shanghai, China (mainland).
authors.forename: Lei
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Organ Transplantation Institute of PLA, Changzheng Hospital, Second Military Medical University, Shanghai, China (mainland).
authors.forename: Jinghui
authors.initials: J
authors.lastname: Yang
authors.affiliation: Organ Transplantation Institute of PLA, Changzheng Hospital, Second Military Medical University, Shanghai, China (mainland).
authors.forename: Li
authors.initials: L
authors.lastname: Zeng
authors.affiliation: Organ Transplantation Institute of PLA, Changzheng Hospital, Second Military Medical University, Shanghai, China (mainland).
authors.forename: Wenyu
authors.initials: W
authors.lastname: Zhao
authors.affiliation: Organ Transplantation Institute of PLA, Changzheng Hospital, Second Military Medical University, Shanghai, China (mainland).
authors.forename: Youhua
authors.initials: Y
authors.lastname: Zhu
mesh_terms: D000225:Adenine; D000293:Adolescent; D000328:Adult; D002681:China; D019343:Citric Acid; D050377:Cold Ischemia; D051799:Delayed Graft Function; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival; D006801:Humans; D006982:Hypertonic Solutions; D007668:Kidney; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D019188:Organ Preservation Solutions; D017063:Outcome Assessment, Health Care; D055815:Young Adult
chemical_list: D006982:Hypertonic Solutions; D019188:Organ Preservation Solutions; D019343:Citric Acid; D000225:Adenine